公司资料
Zevra 股价、新闻与催化剂
- 股票代码:
- ZVRA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
11.87 USD (-0.17%)
收盘价
最后更新: 2026年8月21日
643M USD
市值
股价为何变动
The latest monitored company update is “Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概览
Rare-Disease Commercial Platform
Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases. Its operating model combines direct commercialization, global patient-access programs and development of treatments for small, underserved populations.
MIPLYFFA
MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological manifestations of Niemann-Pick disease type C in patients two years and older. Zevra also operates a global expanded-access program and has submitted a European marketing application.
OLPRUVA
OLPRUVA is an approved formulation of sodium phenylbutyrate for certain urea-cycle disorders, giving Zevra a second commercial product in inherited metabolic disease.
Celiprolol
Celiprolol is an investigational treatment for vascular Ehlers-Danlos syndrome. The event-driven Phase 3 DiSCOVER trial is being conducted under an FDA Special Protocol Assessment.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。